195 related articles for article (PubMed ID: 37531248)
21. Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH.
Coyne GO; Takebe N; Chen AP
Curr Probl Cancer; 2017; 41(3):182-193. PubMed ID: 28372823
[TBL] [Abstract][Full Text] [Related]
22. Perspectives on research activity in the USA on Cancer Precision Medicine.
Bando H; Takebe N
Jpn J Clin Oncol; 2016 Feb; 46(2):106-10. PubMed ID: 26531706
[TBL] [Abstract][Full Text] [Related]
23. The NCI-MATCH trial: lessons for precision oncology.
O'Dwyer PJ; Gray RJ; Flaherty KT; Chen AP; Li S; Wang V; McShane LM; Patton DR; Tricoli JV; Williams PM; Iafrate AJ; Sklar J; Mitchell EP; Takebe N; Sims DJ; Coffey B; Fu T; Routbort M; Rubinstein LV; Little RF; Arteaga CL; Marinucci D; Hamilton SR; Conley BA; Harris LN; Doroshow JH
Nat Med; 2023 Jun; 29(6):1349-1357. PubMed ID: 37322121
[TBL] [Abstract][Full Text] [Related]
24. Basket Trials and the MD Anderson Precision Medicine Clinical Trials Platform.
Said R; Tsimberidou AM
Cancer J; 2019; 25(4):282-286. PubMed ID: 31335392
[TBL] [Abstract][Full Text] [Related]
25. Perspective on Precision Medicine in Oncology.
Johnson TM
Pharmacotherapy; 2017 Sep; 37(9):988-989. PubMed ID: 28632968
[TBL] [Abstract][Full Text] [Related]
26. Personalized Medicine: Genomics Trials in Oncology.
Hayes DF; Schott AF
Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667
[TBL] [Abstract][Full Text] [Related]
27. The NCI-MATCH: A National, Collaborative Precision Oncology Trial for Diverse Tumor Histologies.
Murciano-Goroff YR; Drilon A; Stadler ZK
Cancer Cell; 2021 Jan; 39(1):22-24. PubMed ID: 33434511
[TBL] [Abstract][Full Text] [Related]
28. Evidence-Based Precision Oncology with the Cancer Targetome.
Blucher AS; Choonoo G; Kulesz-Martin M; Wu G; McWeeney SK
Trends Pharmacol Sci; 2017 Dec; 38(12):1085-1099. PubMed ID: 28964549
[TBL] [Abstract][Full Text] [Related]
29. Next-Generation Sequencing in Oncology in the Era of Precision Medicine.
Blumenthal GM; Mansfield E; Pazdur R
JAMA Oncol; 2016 Jan; 2(1):13-4. PubMed ID: 26540172
[No Abstract] [Full Text] [Related]
30. Unlocking multidimensional cancer therapeutics using geometric data science.
Parashar D
Sci Rep; 2023 May; 13(1):8255. PubMed ID: 37217528
[TBL] [Abstract][Full Text] [Related]
31. Light and shadow on innovative clinical trial designs: reflections from the EORTC-PAMM course on 'preclinical and early-phase clinical pharmacology'.
Leonetti A; Boyd L; Giuliani J; Giovannetti E; Garajová I
Expert Rev Clin Pharmacol; 2019 Nov; 12(11):1033-1036. PubMed ID: 31633383
[No Abstract] [Full Text] [Related]
32. Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology.
Tao JJ; Schram AM; Hyman DM
Annu Rev Med; 2018 Jan; 69():319-331. PubMed ID: 29120700
[TBL] [Abstract][Full Text] [Related]
33. Community-driven development of a modified progression-free survival ratio for precision oncology.
Mock A; Heilig CE; Kreutzfeldt S; Huebschmann D; Heining C; Schröck E; Brors B; Stenzinger A; Jäger D; Schlenk R; Glimm H; Fröhling S; Horak P;
ESMO Open; 2019; 4(6):e000583. PubMed ID: 31798980
[TBL] [Abstract][Full Text] [Related]
34. Ushering in the next generation of precision trials for pediatric cancer.
DuBois SG; Corson LB; Stegmaier K; Janeway KA
Science; 2019 Mar; 363(6432):1175-1181. PubMed ID: 30872517
[TBL] [Abstract][Full Text] [Related]
35. From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm.
Adashek JJ; Subbiah V; Kurzrock R
Trends Cancer; 2021 Jan; 7(1):15-28. PubMed ID: 33008795
[TBL] [Abstract][Full Text] [Related]
36. Perspective: The precision-oncology illusion.
Prasad V
Nature; 2016 Sep; 537(7619):S63. PubMed ID: 27602743
[No Abstract] [Full Text] [Related]
37. Patient-centric trials for therapeutic development in precision oncology.
Biankin AV; Piantadosi S; Hollingsworth SJ
Nature; 2015 Oct; 526(7573):361-70. PubMed ID: 26469047
[TBL] [Abstract][Full Text] [Related]
38. A state-of-the-art review of stratified medicine in cancer: towards a future precision medicine strategy in cancer.
Middleton G; Robbins H; Andre F; Swanton C
Ann Oncol; 2022 Feb; 33(2):143-157. PubMed ID: 34808340
[TBL] [Abstract][Full Text] [Related]
39. A Transcriptome-Based Precision Oncology Platform for Patient-Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies.
Mundi PS; Dela Cruz FS; Grunn A; Diolaiti D; Mauguen A; Rainey AR; Guillan K; Siddiquee A; You D; Realubit R; Karan C; Ortiz MV; Douglass EF; Accordino M; Mistretta S; Brogan F; Bruce JN; Caescu CI; Carvajal RD; Crew KD; Decastro G; Heaney M; Henick BS; Hershman DL; Hou JY; Iwamoto FM; Jurcic JG; Kiran RP; Kluger MD; Kreisl T; Lamanna N; Lassman AB; Lim EA; Manji GA; McKhann GM; McKiernan JM; Neugut AI; Olive KP; Rosenblat T; Schwartz GK; Shu CA; Sisti MB; Tergas A; Vattakalam RM; Welch M; Wenske S; Wright JD; Canoll P; Hibshoosh H; Kalinsky K; Aburi M; Sims PA; Alvarez MJ; Kung AL; Califano A
Cancer Discov; 2023 Jun; 13(6):1386-1407. PubMed ID: 37061969
[TBL] [Abstract][Full Text] [Related]
40. Challenges and approaches to implementing master/basket trials in oncology.
Burd A; Schilsky RL; Byrd JC; Levine RL; Papadimitrakopoulou VA; Herbst RS; Redman MW; Druker BJ; Gandara DR
Blood Adv; 2019 Jul; 3(14):2237-2243. PubMed ID: 31337605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
